SCHEMBL4378671

SCHEMBL4378671

CC(C)(C)N(Cc1cccc(C(=O)Nc2ccc(Nc3cc(-c4cccc5c4oc4ccccc45)ncn3)cc2)c1)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.42
PIP4K2C Q8TBX8 2/20 0.41
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
PIP4K2A P48426 4/20 0.40
PIP4K2B P78356 4/20 0.40
PIKFYVE Q9Y2I7 1/20 0.40
LOXL2 Q9Y4K0 2/20 0.39
EGFR P00533 2/20 0.38
ERBB3 P21860 2/20 0.38
CCNT1 O60563 6/20 0.38
CDK9 P50750 6/20 0.38
MCHR1 Q99705 1/20 0.37
ABL1 P00519 1/20 0.36
BCR P11274 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4371518 0.95 ADORA2A (0.45) ADORA2APIP4K2CLMNACYP1A2CYP2D6
SCHEMBL4373522 0.94 PIP4K2C (0.46) ADORA2APIP4K2CLMNACYP1A2CYP2D6
SCHEMBL4382541 0.94 PIP4K2C (0.40) ADORA2APIP4K2CLMNACYP1A2CYP2D6
SCHEMBL4382316 0.92 PIP4K2C (0.40) ADORA2APIP4K2CLMNACYP1A2CYP2D6
SCHEMBL4376893 0.90 CYP1A2 (0.39) ADORA2APIP4K2CLMNACYP1A2CYP2D6
SCHEMBL4382347 0.90 PIP4K2C (0.40) ADORA2APIP4K2CLMNACYP1A2CYP2D6
SCHEMBL4379223 0.89 PIP4K2C (0.42) ADORA2APIP4K2CLMNACYP1A2CYP2D6
SCHEMBL4376878 0.89 PIP4K2C (0.49) ADORA2APIP4K2CLMNACYP1A2CYP2D6
SCHEMBL4384207 0.88 CYP1A2 (0.38) ADORA2APIP4K2CLMNACYP1A2CYP2D6
SCHEMBL28523222 0.88 PIP4K2C (0.44) PIP4K2CLMNACYP1A2CYP2D6PIP4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1763526-B1 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS BAYER SCHERING PHARMA AG (DE) 2009-06-24 EP claimed
CN-112472699-A Combination methods for improving the therapeutic benefit of bisantrene and derivatives 种族肿瘤学公司 2021-03-12 CN disclosed